Poniard Pharmaceuticals, Inc. (OTCPK: PARD)
Health Care · Biotechnology · US
$—
— today · — 1Y
Poniard Pharmaceuticals, Inc. (OTCPK: PARD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $150.00 and employs 7 people.
trading between 0.00 and 0.00.
Tweenvest scores Poniard Pharmaceuticals, Inc. across four factors: quality 8/100. Its strongest factor is quality.
PARD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $150.00
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.79
- Dividend yield
- —
- Beta (5Y)
- -58.34
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 1.50M
- Employees
- 7
- Next earnings
- —
About Poniard Pharmaceuticals, Inc.
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and market introduction of cancer treatments. Its flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, such as small cell lung, colorectal, prostate, and ovarian cancers. The company has advanced Picoplatin through several clinical stages, including a pivotal Phase III SPEAR trial for small cell lung cancer patients in a second-line treatment setting. Furthermore, Phase II studies investigated Picoplatin as an initial therapy for metastatic colorectal cancer and hormone-refractory prostate cancer. An early-stage Phase I trial also examined an oral formulation of Picoplatin for solid tumors. Founded in 1984 as NeoRx Corporation, the company rebranded to Poniard Pharmaceuticals, Inc. in September 2006 and operates from its base in Seattle, Washington.
- ISIN
- US7324494001
- Founded
- 1984
- Listed since
- Aug 11, 1988
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.